Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2022-04-05 Investor Presentation
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Updated Investor Presentation 28 pages 1.3MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's technology platforms, products, pipeline, market overview, financial information, and performance data. It includes forward-looking statements, disclaimers, and detailed slides typical of presentations aimed at investors. There is no indication that this is a regulatory filing, earnings release, or annual report. The length (15,000 characters) and content confirm it is a full presentation document rather than a brief announcement or report publication notice. Therefore, the document fits the category of an Investor Presentation.
2022-04-05 English
INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests 3 pages 199.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new contract and partnership between INOVIQ and ResearchDx for the development and validation of diagnostic tests based on SubB2M technology. It discusses the technology, the agreement terms, and future plans for commercial development. There are no financial statements, regulatory certifications, voting results, or management changes. The content is primarily an update on capitalizing and advancing diagnostic test development, which fits best under Capital/Financing Update (CAP) as it relates to company financing and development activities rather than a full financial report or regulatory filing. The document length is sufficient and contains substantive information about the agreement and development milestones, not just an announcement of a report publication or a brief summary. Therefore, the most appropriate classification is CAP with high confidence.
2022-04-04 English
INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test 4 pages 232.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of a collaboration between INOVIQ and The University of Queensland to develop a novel exosome-based ovarian cancer screening test. It details the scientific background, the grant funding, the collaboration terms, and the potential impact of the project. There are no financial statements, regulatory certifications, voting results, or management changes. The content is focused on a corporate announcement about a research collaboration and product development, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The document fits best as a general regulatory announcement about company activities and collaborations, which falls under Regulatory Filings (RNS).
2022-03-31 English
Update on Legal Proceedings and BARD1 Autoantibody Program 1
Legal Proceedings Report Classification · 95% confidence The document is titled 'UPDATE ON LEGAL PROCEEDINGS AND BARD1 AUTOANTIBODY PROGRAM' and discusses ongoing legal proceedings involving the company INOVIQ Limited. It references a previous announcement and provides details about the legal claim, the company's response, and the status of a related technology program. There are no financial statements, earnings data, or management discussion of financial results. The content focuses solely on legal matters and updates on litigation. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is 3847 characters, which is sufficient to provide substantive information rather than a brief announcement or certification. Hence, the classification is LTR with high confidence.
2022-03-27 English
Appendix 4D and Half Year Financial Report 21 pages 701.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Financial Report for the Half Year ended 31 December 2021' and contains detailed financial statements, directors' report, auditor's review, and notes to the financial statements. It covers a half-year period and includes comprehensive financial data and analysis. The presence of an auditor's review and detailed financial disclosures confirms it is a formal interim financial report. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-02-24 English
Brazilian Patent Issued for Lung & Colorectal Cancer 1
Regulatory Filings Classification · 95% confidence The document is a press release announcing the issuance of a Brazilian patent protecting a specific technology related to BARD1 isoforms for lung and colorectal cancer. It includes details about the patent, its claims, and the company's licensing rights. There is no financial data, regulatory filing, or report content such as annual or quarterly financial results, management discussion, or governance information. The document is an announcement of a patent grant, which is a regulatory or corporate announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2022-02-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.